(Recasts, updates share movement) By Rod Nickel and Ransdell Pierson June 2 (Reuters) – Valeant Pharmaceuticals Inc on Monday prepared to take its $53.8 billion takeover bid for Allergan Inc directly to the Botox maker’s shareholders in a battle that could last late into the year. The fight escalated when Valeant ally Pershing Square, a hedge fund that owns 9.7 percent of Allergan, called for a meeting to replace the company’s board. Pershing Square Chief Executive Officer Bill A
Source: Financials
